{
  "symbol": "ABBV",
  "year": 2024,
  "Period": "Q1",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.2677,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.073
  },
  "top_positive": [
    {
      "sent": "Three months ended September 30, Percent\u00a0change Nine months ended September 30, Percent\u00a0change At\u00a0actual currency\u00a0rates At\u00a0constant currency rates At\u00a0actual currency\u00a0rates At\u00a0constant currency rates (dollars in\u00a0millions) 2024 2023 2024 2023 United States $ 11,148 $ 10,852 2.7 % 2.7 % $ 31,295 $ 30,773 1.7 % 1.7 % International 3,312 3,075 7.7 % 12.4 % 9,937 9,244 7.5 % 12.2 % Net revenues $ 14,460 $ 13,927 3.8 % 4.9 % $ 41,232 $ 40,017 3.0 % 4.1 % 2024 Form 10-Q | 35 The following table details AbbVie\u2019s worldwide net revenues: Three months ended September 30, Percent\u00a0change Nine months ended September 30, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2024 2023 2024 2023 Immunology Humira United States $ 1,765 $ 3,020 (41.6) % (41.6) % $ 5,896 $ 9,420 (37.4) % (37.4) % International 462 527 (12.4) % (7.8) % 1,415 1,680 (15.8) % (10.8) % Total $ 2,227 $ 3,547 (37.2) % (36.5) % $ 7,311 $ 11,100 (34.1) % (33.3) % Skyrizi United States $ 2,778 $ 1,875 48.3 % 48.3 % $ 6,774 $ 4,648 45.8 % 45.8 % International 427 251 70.0 % 75.7 % 1,166 721 61.8 % 66.6 % Total $ 3,205 $ 2,126 50.8 % 51.5 % $ 7,940 $ 5,369 47.9 % 48.5 % Rinvoq United States $ 1,170 $ 801 45.9 % 45.9 % $ 2,912 $ 1,895 53.6 % 53.6 % International 444 309 44.0 % 51.6 % 1,225 819 49.6 % 58.5 % Total $ 1,614 $ 1,110 45.3 % 47.4 % $ 4,137 $ 2,714 52.4 % 55.1 % Oncology Imbruvica United States $ 618 $ 678 (8.9) % (8.9) % $ 1,823 $ 1,982 (8.0) % (8.0) % Collaboration revenues 210 230 (8.4) % (8.4) % 676 711 (4.9) % (4.9) % Total $ 828 $ 908 (8.8) % (8.8) % $ 2,499 $ 2,693 (7.2) % (7.2) % Venclexta United States $ 340 $ 281 21.5 % 21.5 % $ 921 $ 811 13.6 % 13.6 % International 337 309 8.9 % 15.4 % 1,007 888 13.4 % 19.7 % Total $ 677 $ 590 14.8 % 18.2 % $ 1,928 $ 1,699 13.5 % 16.8 % Elahere (a) United States $ 139 $ \u2014 n/m n/m $ 331 $ \u2014 n/m n/m Epkinly Collaboration revenues $ 31 $ 14 >100.0 % >100.0 % $ 82 $ 14 >100.0 % >100.0 % International 12 \u2014 >100.0 % >100.0 % 24 \u2014 >100.0 % >100.0 % Total $ 43 $ 14 >100.0 % >100.0 % $ 106 $ 14 >100.0 % >100.0 % Aesthetics Botox Cosmetic United States $ 414 $ 388 6.5 % 6.5 % $ 1,253 $ 1,217 2.9 % 2.9 % International 257 232 10.9 % 15.5 % 780 747 4.5 % 9.1 % Total $ 671 $ 620 8.2 % 9.9 % $ 2,033 $ 1,964 3.5 % 5.3 % Juvederm Collection United States $ 105 $ 116 (10.2) % (10.2) % $ 349 $ 363 (4.1) % (4.1) % International 153 205 (25.1) % (20.8) % 549 681 (19.3) % (14.6) % Total $ 258 $ 321 (19.7) % (16.9) % $ 898 $ 1,044 (14.0) % (10.9) % Other Aesthetics United States $ 272 $ 255 6.4 % 6.4 % $ 828 $ 785 5.6 % 5.6 % International 38 43 (10.0) % (2.0) % 119 130 (8.7) % (1.8) % Total $ 310 $ 298 4.0 % 5.1 % $ 947 $ 915 3.5 % 4.5 % Neuroscience Botox Therapeutic United States $ 708 $ 626 13.1 % 13.1 % $ 1,988 $ 1,827 8.8 % 8.8 % International 140 122 14.6 % 20.7 % 422 388 8.6 % 13.1 % Total $ 848 $ 748 13.4 % 14.4 % $ 2,410 $ 2,215 8.8 % 9.6 % Vraylar United States $ 873 $ 750 16.5 % 16.5 % $ 2,338 $ 1,967 18.9 % 18.9 % International 2 1 49.3 % 51.9 % 5 3 76.0 % 76.9 % Total $ 875 $ 751 16.6 % 16.6 % $ 2,343 $ 1,970 18.9 % 18.9 % Duodopa United States $ 24 $ 25 (4.7) % (4.7) % $ 72 $ 74 (3.3) % (3.3) % International 87 93 (7.1) % (6.4) % 267 279 (4.4) % (4.0) % Total $ 111 $ 118 (6.6) % (6.0) % $ 339 $ 353 (4.1) % (3.8) % Ubrelvy United States $ 261 $ 230 13.6 % 13.6 % $ 685 $ 574 19.3 % 19.3 % International 8 3 >100.0 % >100.0 % 18 7 >100.0 % >100.0 % Total $ 269 $ 233 15.3 % 15.3 % $ 703 $ 581 20.9 % 20.9 % Qulipta United States $ 168 $ 131 28.3 % 28.3 % $ 442 $ 292 51.3 % 51.3 % International 8 1 >100.0 % >100.0 % 15 2 >100.0 % >100.0 % Total $ 176 $ 132 33.6 % 33.6 % $ 457 $ 294 55.5 % 55.5 % 2024 Form 10-Q | 36 Three months ended September 30, Percent\u00a0change Nine months ended September 30, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2024 2023 2024 2023 Other Neuroscience United States $ 54 $ 55 (4.1) % (4.1) % $ 172 $ 195 (11.6) % (11.6) % International 30 6 >100.0 % >100.0 % 66 15 >100.0 % >100.0 % Total $ 84 $ 61 36.4 % 37.1 % $ 238 $ 210 13.5 % 14.1 % Eye Care Ozurdex United States $ 33 $ 34 (2.3) % (2.3) % $ 102 $ 107 (4.4) % (4.4) % International 86 86 (0.3) % 2.5 % 272 247 10.0 % 13.1 % Total $ 119 $ 120 (0.9) % 1.1 % $ 374 $ 354 5.7 % 7.8 % Lumigan/Ganfort United States $ 58 $ 28 >100.0 % >100.0 % $ 129 $ 142 (9.5) % (9.5) % International 58 63 (7.0) % (2.7) % 181 198 (8.7) % (5.9) % Total $ 116 $ 91 27.2 % 30.2 % $ 310 $ 340 (9.0) % (7.4) % Alphagan/Combigan United States $ 26 $ 30 (15.3) % (15.3) % $ 54 $ 90 (40.3) % (40.3) % International 36 40 (10.0) % (4.5) % 116 116 (0.1) % 6.9 % Total $ 62 $ 70 (12.3) % (9.2) % $ 170 $ 206 (17.7) % (13.8) % Restasis United States $ 8 $ 104 (92.5) % (92.5) % $ 70 $ 265 (73.4) % (73.4) % International 13 13 2.1 % 8.1 % 40 43 (7.4) % (2.2) % Total $ 21 $ 117 (82.2) % (81.5) % $ 110 $ 308 (64.2) % (63.5) % Other Eye Care United States $ 115 $ 114 1.7 % 1.7 % $ 351 $ 334 5.3 % 5.3 % International 92 93 (2.0) % 4.2 % 281 288 (2.4) % 2.1 % Total $ 207 $ 207 \u2014 % 2.8 % $ 632 $ 622 1.7 % 3.8 % Other Key Products Mavyret United States $ 147 $ 167 (12.7) % (12.7) % $ 458 $ 531 (13.9) % (13.9) % International 155 203 (23.1) % (20.5) % 562 590 (4.6) % (1.2) % Total $ 302 $ 370 (18.4) % (17.0) % $ 1,020 $ 1,121 (9.0) % (7.2) % Creon United States $ 338 $ 305 10.6 % 10.6 % $ 995 $ 892 11.5 % 11.5 % Linzess/Constella United States $ 225 $ 279 (19.2) % (19.2) % $ 693 $ 799 (13.2) % (13.2) % International 9 9 0.4 % 2.0 % 28 26 6.2 % 6.0 % Total $ 234 $ 288 (18.6) % (18.6) % $ 721 $ 825 (12.6) % (12.6) % All other $ 726 $ 782 (6.8) % (5.5) % $ 2,280 $ 2,214 3.0 % 4.6 % Total net revenues $ 14,460 $ 13,927 3.8 % 4.9 % $ 41,232 $ 40,017 3.0 % 4.1 % n/m \u2013 Not meaningful (a) Net revenues include ImmunoGen product revenues after the acquisition closing date of February 12, 2024.",
      "score": 0.996
    },
    {
      "sent": "AbbVie intends to execute its strategy and advance its mission in a number of ways, including: (i) maximizing the benefits of a diversified revenue base with multiple long-term growth drivers; (ii) leveraging AbbVie's commercial strength and international infrastructure across therapeutic areas and ensuring strong commercial execution of new product launches; (iii)\u00a0continuing to invest in and expand its pipeline in support of opportunities in immunology, oncology, aesthetics, neuroscience and eye care as well as continued investment in key on-market products; (iv)\u00a0generating substantial operating cash flows to support investment in innovative research and development, and return cash to shareholders via a strong and growing dividend while also continuing to repay debt.",
      "score": 0.986
    },
    {
      "sent": "AbbVie intends to execute its strategy and advance its mission in a number of ways, including: (i) maximizing the benefits of a diversified revenue base with multiple long-term growth drivers; (ii) leveraging AbbVie's commercial strength and international infrastructure across therapeutic areas and ensuring strong commercial execution of new product launches; (iii)\u00a0continuing to invest in and expand its pipeline in support of opportunities in immunology, oncology, aesthetics, neuroscience and eye care as well as continued investment in key on-market products; (iv)\u00a0generating substantial operating cash flows to support investment in innovative research and development, and return cash to shareholders via a strong and growing dividend while also continuing to repay debt.",
      "score": 0.986
    }
  ],
  "top_negative": [
    {
      "sent": "Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or 2024 Form 10-Q | 42 that all control issues and instances of fraud, if any, have been detected.",
      "score": -0.8779
    },
    {
      "sent": "Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or 2024 Form 10-Q | 42 that all control issues and instances of fraud, if any, have been detected.",
      "score": -0.8779
    },
    {
      "sent": "Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or 2024 Form 10-Q | 42 that all control issues and instances of fraud, if any, have been detected.",
      "score": -0.8779
    }
  ],
  "forward_snippets": [
    "AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements.",
    "AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements.",
    "Cerevel Therapeutics neuroscience pipeline includes multiple clinical-stage and preclinical candidates with the potential to treat several diseases including schizophrenia, Parkinson's disease and mood disorders.",
    "Some of the more significant assumptions inherent in the development of these asset valuations \nguidance on its consolidated financial statements.",
    "AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements."
  ],
  "curated_text": "Symbol: ABBV. Year: 2024. Period: Q1. ReportType: Q10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: Three months ended September 30, Percent\u00a0change Nine months ended September 30, Percent\u00a0change At\u00a0actual currency\u00a0rates At\u00a0constant currency rates At\u00a0actual currency\u00a0rates At\u00a0constant currency rates (dollars in\u00a0millions) 2024 2023 2024 2023 United States $ 11,148 $ 10,852 2.7 % 2.7 % $ 31,295 $ 30,773 1.7 % 1.7 % International 3,312 3,075 7.7 % 12.4 % 9,937 9,244 7.5 % 12.2 % Net revenues $ 14,460 $ 13,927 3.8 % 4.9 % $ 41,232 $ 40,017 3.0 % 4.1 % 2024 Form 10-Q | 35 The following table details AbbVie\u2019s worldwide net revenues: Three months ended September 30, Percent\u00a0change Nine months ended September 30, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2024 2023 2024 2023 Immunology Humira United States $ 1,765 $ 3,020 (41.6) % (41.6) % $ 5,896 $ 9,420 (37.4) % (37.4) % International 462 527 (12.4) % (7.8) % 1,415 1,680 (15.8) % (10.8) % Total $ 2,227 $ 3,547 (37.2) % (36.5) % $ 7,311 $ 11,100 (34.1) % (33.3) % Skyrizi United States $ 2,778 $ 1,875 48.3 % 48.3 % $ 6,774 $ 4,648 45.8 % 45.8 % International 427 251 70.0 % 75.7 % 1,166 721 61.8 % 66.6 % Total $ 3,205 $ 2,126 50.8 % 51.5 % $ 7,940 $ 5,369 47.9 % 48.5 % Rinvoq United States $ 1,170 $ 801 45.9 % 45.9 % $ 2,912 $ 1,895 53.6 % 53.6 % International 444 309 44.0 % 51.6 % 1,225 819 49.6 % 58.5 % Total $ 1,614 $ 1,110 45.3 % 47.4 % $ 4,137 $ 2,714 52.4 % 55.1 % Oncology Imbruvica United States $ 618 $ 678 (8.9) % (8.9) % $ 1,823 $ 1,982 (8.0) % (8.0) % Collaboration revenues 210 230 (8.4) % (8.4) % 676 711 (4.9) % (4.9) % Total $ 828 $ 908 (8.8) % (8.8) % $ 2,499 $ 2,693 (7.2) % (7.2) % Venclexta United States $ 340 $ 281 21.5 % 21.5 % $ 921 $ 811 13.6 % 13.6 % International 337 309 8.9 % 15.4 % 1,007 888 13.4 % 19.7 % Total $ 677 $ 590 14.8 % 18.2 % $ 1,928 $ 1,699 13.5 % 16.8 % Elahere (a) United States $ 139 $ \u2014 n/m n/m $ 331 $ \u2014 n/m n/m Epkinly Collaboration revenues $ 31 $ 14 >100.0 % >100.0 % $ 82 $ 14 >100.0 % >100.0 % International 12 \u2014 >100.0 % >100.0 % 24 \u2014 >100.0 % >100.0 % Total $ 43 $ 14 >100.0 % >100.0 % $ 106 $ 14 >100.0 % >100.0 % Aesthetics Botox Cosmetic United States $ 414 $ 388 6.5 % 6.5 % $ 1,253 $ 1,217 2.9 % 2.9 % International 257 232 10.9 % 15.5 % 780 747 4.5 % 9.1 % Total $ 671 $ 620 8.2 % 9.9 % $ 2,033 $ 1,964 3.5 % 5.3 % Juvederm Collection United States $ 105 $ 116 (10.2) % (10.2) % $ 349 $ 363 (4.1) % (4.1) % International 153 205 (25.1) % (20.8) % 549 681 (19.3) % (14.6) % Total $ 258 $ 321 (19.7) % (16.9) % $ 898 $ 1,044 (14.0) % (10.9) % Other Aesthetics United States $ 272 $ 255 6.4 % 6.4 % $ 828 $ 785 5.6 % 5.6 % International 38 43 (10.0) % (2.0) % 119 130 (8.7) % (1.8) % Total $ 310 $ 298 4.0 % 5.1 % $ 947 $ 915 3.5 % 4.5 % Neuroscience Botox Therapeutic United States $ 708 $ 626 13.1 % 13.1 % $ 1,988 $ 1,827 8.8 % 8.8 % International 140 122 14.6 % 20.7 % 422 388 8.6 % 13.1 % Total $ 848 $ 748 13.4 % 14.4 % $ 2,410 $ 2,215 8.8 % 9.6 % Vraylar United States $ 873 $ 750 16.5 % 16.5 % $ 2,338 $ 1,967 18.9 % 18.9 % International 2 1 49.3 % 51.9 % 5 3 76.0 % 76.9 % Total $ 875 $ 751 16.6 % 16.6 % $ 2,343 $ 1,970 18.9 % 18.9 % Duodopa United States $ 24 $ 25 (4.7) % (4.7) % $ 72 $ 74 (3.3) % (3.3) % International 87 93 (7.1) % (6.4) % 267 279 (4.4) % (4.0) % Total $ 111 $ 118 (6.6) % (6.0) % $ 339 $ 353 (4.1) % (3.8) % Ubrelvy United States $ 261 $ 230 13.6 % 13.6 % $ 685 $ 574 19.3 % 19.3 % International 8 3 >100.0 % >100.0 % 18 7 >100.0 % >100.0 % Total $ 269 $ 233 15.3 % 15.3 % $ 703 $ 581 20.9 % 20.9 % Qulipta United States $ 168 $ 131 28.3 % 28.3 % $ 442 $ 292 51.3 % 51.3 % International 8 1 >100.0 % >100.0 % 15 2 >100.0 % >100.0 % Total $ 176 $ 132 33.6 % 33.6 % $ 457 $ 294 55.5 % 55.5 % 2024 Form 10-Q | 36 Three months ended September 30, Percent\u00a0change Nine months ended September 30, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2024 2023 2024 2023 Other Neuroscience United States $ 54 $ 55 (4.1) % (4.1) % $ 172 $ 195 (11.6) % (11.6) % International 30 6 >100.0 % >100.0 % 66 15 >100.0 % >100.0 % Total $ 84 $ 61 36.4 % 37.1 % $ 238 $ 210 13.5 % 14.1 % Eye Care Ozurdex United States $ 33 $ 34 (2.3) % (2.3) % $ 102 $ 107 (4.4) % (4.4) % International 86 86 (0.3) % 2.5 % 272 247 10.0 % 13.1 % Total $ 119 $ 120 (0.9) % 1.1 % $ 374 $ 354 5.7 % 7.8 % Lumigan/Ganfort United States $ 58 $ 28 >100.0 % >100.0 % $ 129 $ 142 (9.5) % (9.5) % International 58 63 (7.0) % (2.7) % 181 198 (8.7) % (5.9) % Total $ 116 $ 91 27.2 % 30.2 % $ 310 $ 340 (9.0) % (7.4) % Alphagan/Combigan United States $ 26 $ 30 (15.3) % (15.3) % $ 54 $ 90 (40.3) % (40.3) % International 36 40 (10.0) % (4.5) % 116 116 (0.1) % 6.9 % Total $ 62 $ 70 (12.3) % (9.2) % $ 170 $ 206 (17.7) % (13.8) % Restasis United States $ 8 $ 104 (92.5) % (92.5) % $ 70 $ 265 (73.4) % (73.4) % International 13 13 2.1 % 8.1 % 40 43 (7.4) % (2.2) % Total $ 21 $ 117 (82.2) % (81.5) % $ 110 $ 308 (64.2) % (63.5) % Other Eye Care United States $ 115 $ 114 1.7 % 1.7 % $ 351 $ 334 5.3 % 5.3 % International 92 93 (2.0) % 4.2 % 281 288 (2.4) % 2.1 % Total $ 207 $ 207 \u2014 % 2.8 % $ 632 $ 622 1.7 % 3.8 % Other Key Products Mavyret United States $ 147 $ 167 (12.7) % (12.7) % $ 458 $ 531 (13.9) % (13.9) % International 155 203 (23.1) % (20.5) % 562 590 (4.6) % (1.2) % Total $ 302 $ 370 (18.4) % (17.0) % $ 1,020 $ 1,121 (9.0) % (7.2) % Creon United States $ 338 $ 305 10.6 % 10.6 % $ 995 $ 892 11.5 % 11.5 % Linzess/Constella United States $ 225 $ 279 (19.2) % (19.2) % $ 693 $ 799 (13.2) % (13.2) % International 9 9 0.4 % 2.0 % 28 26 6.2 % 6.0 % Total $ 234 $ 288 (18.6) % (18.6) % $ 721 $ 825 (12.6) % (12.6) % All other $ 726 $ 782 (6.8) % (5.5) % $ 2,280 $ 2,214 3.0 % 4.6 % Total net revenues $ 14,460 $ 13,927 3.8 % 4.9 % $ 41,232 $ 40,017 3.0 % 4.1 % n/m \u2013 Not meaningful (a) Net revenues include ImmunoGen product revenues after the acquisition closing date of February 12, 2024. AbbVie intends to execute its strategy and advance its mission in a number of ways, including: (i) maximizing the benefits of a diversified revenue base with multiple long-term growth drivers; (ii) leveraging AbbVie's commercial strength and international infrastructure across therapeutic areas and ensuring strong commercial execution of new product launches; (iii)\u00a0continuing to invest in and expand its pipeline in support of opportunities in immunology, oncology, aesthetics, neuroscience and eye care as well as continued investment in key on-market products; (iv)\u00a0generating substantial operating cash flows to support investment in innovative research and development, and return cash to shareholders via a strong and growing dividend while also continuing to repay debt. AbbVie intends to execute its strategy and advance its mission in a number of ways, including: (i) maximizing the benefits of a diversified revenue base with multiple long-term growth drivers; (ii) leveraging AbbVie's commercial strength and international infrastructure across therapeutic areas and ensuring strong commercial execution of new product launches; (iii)\u00a0continuing to invest in and expand its pipeline in support of opportunities in immunology, oncology, aesthetics, neuroscience and eye care as well as continued investment in key on-market products; (iv)\u00a0generating substantial operating cash flows to support investment in innovative research and development, and return cash to shareholders via a strong and growing dividend while also continuing to repay debt. Top negative sentences: Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or 2024 Form 10-Q | 42 that all control issues and instances of fraud, if any, have been detected. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or 2024 Form 10-Q | 42 that all control issues and instances of fraud, if any, have been detected. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or 2024 Form 10-Q | 42 that all control issues and instances of fraud, if any, have been detected. Forward-looking snippets: AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements. AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements. Cerevel Therapeutics neuroscience pipeline includes multiple clinical-stage and preclinical candidates with the potential to treat several diseases including schizophrenia, Parkinson's disease and mood disorders. Some of the more significant assumptions inherent in the development of these asset valuations \nguidance on its consolidated financial statements. AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements."
}